Special Issue "Transplantation of Glial Cells to Repair Injuries and Diseases of the Nervous System"

A special issue of Neuroglia (ISSN 2571-6980).

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 2708

Special Issue Editors

Griffith Institute for Drug Discovery, Griffith University, 170 Kessels Road Nathan, Brisbane, QLD 4111, Australia
Interests: olfactory ensheathing cells; schwann cells; spinal cord injury; peripheral nerve injury; cell transplantation; 3D bioprinting; neurodegenerative disease; growth factor
Special Issues, Collections and Topics in MDPI journals
Menzies Health Institute Queensland, Griffith University, University Drive, Southport, QLD 4222, Australia
Interests: glial cell; cell culture; transplantation; three-dimensional; fibroblast; bioengineering; 3D printing; scaffold; bioemedical device

Special Issue Information

Dear Colleagues,

The transplantation of glial cells to repair injuries and diseases of the nervous system is a growing field, and many promising outcomes have been demonstrated in various injury models. For example, various types of glial cells have been tested in pre-clinical and clinical trials to repair spinal cord injury, peripheral nerve injury including optic nerve and brachial plexus injuries, and brain injury, and to treat demyelinating diseases and neurodegeneration. 

Regardless of the injury model or cell transplantation type, some of the difficulties in optimising glial cell transplantation include the purification of glial cells, the timing of transplantation, the cell preparation and supporting scaffolds, the surgical approach of transplantation, the survival of the transplanted cells, and the various assessments of regeneration. 

This Special Issue seeks original research articles and reviews that address the latest approaches used for glial cell transplantation. Topics can include, but are not limited to, glial cell transplantation that involves new cell-preparation technologies; methods to improve cell survival after transplantation; timing and method of transplantation; and motor, sensory and autonomic tests to determine functional outcomes. By gathering these submissions into one Special Issue, we aim to promote new ideas that can be adopted by others to improve outcomes for a range of neural therapies. 

Prof. Dr. James St John
Dr. Mo Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Neuroglia is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • schwann cell
  • oligodendrocyte
  • olfactory ensheathing cell
  • astrocyte
  • spinal cord injury
  • nerve injury
  • bioengineering, scaffold
  • nerve conduit
  • tissue engineering

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Transplantation of Olfactory Ensheathing Cells: Properties and Therapeutic Effects after Transplantation into the Lesioned Nervous System
Neuroglia 2022, 3(1), 1-22; https://doi.org/10.3390/neuroglia3010001 - 28 Jan 2022
Cited by 1 | Viewed by 2156
The primary olfactory system (POS) is in permanent renewal, especially the primary olfactory neurons (PON) are renewed with a turnover of around four weeks, even in adulthood. The re-growth of these axons is helped by a specific population of glial cells: the olfactory [...] Read more.
The primary olfactory system (POS) is in permanent renewal, especially the primary olfactory neurons (PON) are renewed with a turnover of around four weeks, even in adulthood. The re-growth of these axons is helped by a specific population of glial cells: the olfactory ensheathing cells (OECs). In the POS, OECs constitute an “open-channel” in which the axons of PON cause regrowth from peripheral nervous system (PNS) to central nervous system (CNS). The remarkable role played by OECs into the POS has led scientists to investigate their properties and potential beneficial effects after transplantation in different lesion models of the CNS and PNS. In this review, we will resume and discuss more than thirty years of research regarding OEC studies. Indeed, after discussing the embryonic origins of OECs, we will describe the in vitro and in vivo properties exert at physiological state by these cells. Thereafter, we will present and talk over the effects of the transplantation of OECs after spinal cord injury, peripheral injury and other CNS injury models such as demyelinating diseases or traumatic brain injury. Finally, the mechanisms exerted by OECs in these different CNS and PNS lesion paradigms will be stated and we will conclude by presenting the innovations and future directions which can be considered to improve OECs properties and allow us to envisage their use in the near future in clinical applications. Full article
Show Figures

Figure 1

Back to TopTop